XFOR — X4 Pharmaceuticals, Inc

—
Nasdaq · Health Care · Biotechnology · CIK 1501697 ·
Last close
$3.09
Market Cap
$315.53M
52W High
$4.83
52W Low
$2.43
ADV30
715,995
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,879,000 2,366,000 -19,991,000 -20,198,000 231,816,000 185,801,000 92,933,000
Jun 2026 8,806,000 7,189,000 -16,391,000 -16,157,000 253,063,000 195,095,000 97,609,000
Mar 2026 2,708,000 2,110,000 -20,306,000 -20,241,000 270,281,000 216,908,000 101,831,000
Dec 2025 2,568,000 2,204,000 -23,699,000 -23,925,000 290,461,000 217,049,000 104,171,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-76,100,000
Investing CF
$46,101,000
Financing CF
$146,057,000
CapEx
$-3,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.14
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-651,150,000
Inventory
$5,507,000
Receivables
$1,470,000
ST Investments
$1,900,000
EBIT TTM
$-71,838,000
Pretax Income TTM
$-80,516,000
Interest Exp TTM
$8,678,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$16,961,000
EBITDA
$-71,378,000
Free Cash Flow
$-49,505,752
Enterprise Value
$214,216,096
Total Cash
$187,700,992
Total Debt
$77,196,000
Shares Out
102,113,554
Trailing EPS
$0.55
Book Value
$1.38
ROE
-80.3%
ROA
-23.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 35,113,000 -86,883,000 -79,199,000 290,461,000 104,171,000 186,290,000 -85,618,000
Dec 2024 2,557,000 -141,401,000 -37,450,000 146,447,000 124,298,000 22,149,000 -130,901,000
Dec 2023 0 -107,522,000 -101,167,000 147,258,000 96,159,000 51,099,000 -96,512,000
Dec 2022 0 -88,078,000 -93,867,000 155,586,000 81,535,000 74,051,000 -77,102,000

TTM Snapshot

Revenues TTM
$15,847,000
NetIncome TTM
$-90,138,000
OpCashFlow TTM
—
Assets (Latest)
$253,063,000
Forward EPS
$-0.77

Peers — same industry

TickerNameMarket CapLastDaily %
CCCC C4 Therapeutics, Inc. $332.23M $2.53 —
SCTX Scribe Therapeutics, Inc. $298.64M $15.77 —
KYTX Kyverna Therapeutics, Inc. $297.14M $4.70 —
AGMB AgomAb Therapeutics NV $291.55M $5.92 —
AUTL Autolus Therapeutics plc $290.12M $1.09 —

News headlines (Yahoo Finance, 1h cache)

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
2026-11-04 21:50 · Yahoo
X4 Pharmaceuticals: Q3 Earnings Snapshot
2026-11-04 21:31 · Yahoo
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-04 21:15 · Yahoo
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
2026-11-03 21:30 · Yahoo
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
2026-10-29 20:30 · Yahoo
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
2026-10-29 20:14 · Yahoo
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
2026-10-09 11:00 · Yahoo
X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures
2026-10-08 12:30 · Yahoo
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
2026-10-08 11:00 · Yahoo
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.